|
À̳뿡ÀÌÄ¡¾ËÄÁ¼³Æà |
[¹ÙÀÌ¿À±â¾÷] MIS ´ã´ç ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
2³â¡è |
ä¿ë½Ã |
06.15 |
|
|
À̳뿡ÀÌÄ¡¾ËÄÁ¼³Æà |
[¿Ü±¹°èÁ¦¾àȸ»ç] CRA ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
06.15 |
|
|
¿¡À̽ºÆÄÆ®³Ê½º |
±¹³» Á¦¾àȸ»ç Sr.CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
02.18 |
|
|
¿¡À̽ºÆÄÆ®³Ê½º |
±¹³» ´ëÇü CRO CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
02.18 |
|
|
ºê·¹ÀÎÇãºê |
[ÇìµåÇåÆÃ]±Û·Î¹ú ¸ÞµðÄà Áø´ÜÀåºñ ȸ»ç-ÀÓ»ó °æ·ÂÀÚ Ã¤¿ë
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
09.23 |
|
|
ICON Clinical Research Korea |
Study Start-up Associate
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
¿¡À̽ºÆÄÆ®³Ê½º |
¿Ü±¹°è Á¦¾àȸ»ç Sr.CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
02.18 |
|
|
ICON Clinical Research Korea |
Jr. Clinical Research Associate(Oncology)
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
Æ÷Ƽ½ºÆÄÆ®³Ê½º |
¿Ü±¹°è Á¦¾à»ç °¡Á¤ÀÇÇаú, ³»ºÐºñ°ú, ¼øȯ±â°ú MD ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
2³â¡è |
ä¿ë½Ã |
03.24 |
|
|
´º¸ÞÀ̽º |
[ÃÖ»óÀ§ ´ë¿ì] ±ÔÁ¦°úÇÐ Àü¹®°¡ RA ºñÀÓ»ó ÀÓ»ó ÀÎÇã°¡ Àü¹®
¼¿ï ¼´ë¹®±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
2³â¡è |
ä¿ë½Ã |
06.01 |
|
|
InnoHR |
¼¼°èÀûÀÎ ¸ÞµðÄà ±×·ì RA Specialist
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
2³â¡è |
ä¿ë½Ã |
04.18 |
|
|
µå¸²¼Ö·ç¼Ç |
Á¦¾àºÐ¾ß ±×·ì»çÀÇ ITÀü¹®±â¾÷ÀÇ ÀÀ¿ëÇÁ·Î±×·¥ °³¹ßºÎ¹® °æ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
2³â¡è |
ä¿ë½Ã |
10.28 |
|
|
(ÁÖ)¹Ì½Ã°£ÄÁ¼³Æà |
¿Ü±¹°èÁ¦¾à±â¾÷ CRA °æ·Â3³âÀÌ»ó
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
05.14 |
|
|
µ¿¹æ¿¡ÇÁƼ¿¤(ÁÖ) |
õ¿¬¹° »ç¾÷ÆÀ ä¿ë °ø°í (¿¬±¸ ¹× »ý»ê°ü¸®)
°æ±â ȼº½Ã | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
2³â¡è |
ä¿ë½Ã |
06.30 |
|
|
PPD Development Pte. Ltd. |
SCRA ¹× CRA II ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
06.07 |
|